Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia
- 1 March 2003
- Vol. 61 (3) , 579-584
- https://doi.org/10.1016/s0090-4295(02)02401-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- IMPACT OF PROSTATE SIZE ON RESPONSE TO MEDICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH)Journal of Urology, 1999
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- The relationship between sexual life and urinary condition in the French communityJournal of Clinical Epidemiology, 1996
- The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic HyperplasiaNew England Journal of Medicine, 1996
- Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled studyUrology, 1995
- Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- A Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic HyperplasiaNew England Journal of Medicine, 1995
- The Effect of Finasteride in Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1992
- Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditismNature, 1991
- Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male PseudohermaphroditismScience, 1974